HAMA2 response (10, 11) that can render them ineffective for repeat therapy. Second, the half-life of murine antibodies in the circulation is relatively short (1â€"2 days) compared to human immunoglobulins (2â€"3 weeks; Refs. 12 and 13). Third, the Fc portion of murine antibodies may not elicit CDC or ADCC as effectively as the Fc portion of a human antibody (14, 15) . To address these problems, recombinant DNA technologies have been applied initially to develop mouse/ human chimeric antibodies (16) containing the variable region of the murine antibody and the constant region of a human antibody. How ever, chimeric antibodies may still provoke a substantial HAMA response because one third of the molecule is still of murine origin (17). To reduce further the immunogenicity of chimeric antibodies and to prolong half-life, humanized antibodies have been constructed by combining only the smallest required part of a mouse antibody, the CDRs, with human variable region frameworks and constant regions
(18).
In this study, we initially constructed two chimeric antibodies of human IgGl and IgG3 isotypes from the murine ABL 364 and evaluated their abilities to mediate CDC and ADCC against several human tumor cell lines, including breast, colon, gastric, and lung, in comparison to the parent murine IgG3. We then constructed a series of humanized antibody variants of IgG1 isotype and studied their binding affinities and effector functions. While studying the variants, we observed that a single amino acid substitution in the variable domain of heavy chain has a significant effect in determining how well the antibody can be expressed. The best humanized ABL 364 antibody variant has high affinity and specificity for the Lewis Y antigen and retains potent cytolytic activities toward several tumor cell lines, and can be expressed at a high level. Pharmacokinetics of this humanized antibody was evaluated in rhesus monkeys in com parison to the munne antibody.
MATERIALS AND METHODS
Cell Lines. ABL 364 (BR55â€"2)is secreted by a hybridoma generated by fusion of splenocytes of a BALB/c mouse immunized using the MCF7 breast carcinoma cell line with the 653 variant of the P3X63Ag8 murine myeloma (1, 2). MCF7, SKBR3, and SW948 were obtainedfrom AmericanType Culture Collection. SKBRS, CATO, and SW2 were obtained from the Wistar Institute (Philadelphia, PA).
Cloning of V Region cDNAs. The variable domain cDNAs of the light and heavy chains of munne ABL 364 was cloned by the anchored PCR method (19) using 3' primers that hybridized to the C regions and 5' primers that hybridized to the G-tails attached to the cDNA using terminal deoxytrans ferase. The sequences were determined using the dideoxy termination method on an Applied Biosystems 373A automated sequencer.
Expression Vectors. Separate expression vectors were constructed con mining human light and heavy chain constant regions: pVk for the human ic light chain, pVgl for the human yl heavy chain, and pVg3 for the human y3 heavy chain. These expression vectors have been described in detail previously (19) . For construction of chimeric and humanized antibodies, the variable Pharmacoidnetics of the humanized ABL 364 antibody variant K was compared with that of the parent murine antibody in rhesus monkeys. It was shown that the terminal half-life of the humanized antibody in rhesus
INTRODUCTION
A blood group-related carbohydrate, the Y difucosylated hapten (the Lewis Y antigen), has been found to be associated with 60â€"90% of human carcinomas of epithelial cell origin including breast, colon, gastric, and lung cancers ( 1, 2). The level of expression of the antigen has also been shown to correlate with survival in patients with carcinoma of the lung (3). Several murine antibodies have been generated against this antigen to explore their antitumor activities (1, 4, 5) . The monoclonal antibody ABL 364 (formerly designated BR55â€"2in previous literature) is a murine IgG3 that is highly specific for the Lewis Y carbohydrate antigen, and has shown significant in vitro and in vivo antitumor cytolytic activity (1, 2, 6, 7). The antibody activates both human complement and human effector cells in vitro for tumor cell lysis (6, 7) , and has been tested in several clinical trials including two Phase I/I! trials in relapsed small cell lung cancer and metastatic breast cancer (8, 9) . In the latter trial, it was shown that i.v. administration of murine ABL 364 can substantially reduce or dim mate Y antigen-positive cytokeratin-positive cells (â€oemicrometasta sesâ€•) in the bone marrow of patients with breast carcinoma (9) . There are, however, several drawbacks in using murine antibodies for ther apeutic purposes in humans. First, such antibodies usually induce a experimental release â€" spontaneous release total release â€" spontaneous release HUMANIZED ANTI-LEWIS Y ANTIBODIES region cDNAs of the murine or humanized antibodies can be inserted into thesodium azide. After incubation, cells were washed, centrifuged, and resus
XbaI sites of the corresponding expression vectors (19 the heavy chain variants, oligonucleotides with the desired sequencesusing the Bolton-Hunter method (21) , and radioactivity of supematants andwere synthesized and incorporated into the variable region gene using the PCR. Before transfection, the light chain and heavy chain containingplasmids were linearized using BamHl, extracted with phenol-chloroform, andethanol precipitated. All transfections were done using 20 @g plasmid DNAand about i0@cells in PBS. The cells from each transfection were plated intoone 96-well tissue culture plate. After 48 h, selective medium was applied.Cells were selected in DMEM + 10% FBS + HT media supplement (Sigma,St.
Louis, MO) + 1 @.tg/ml mycophenolic acid. After the wells had becomeconfluent with surviving colonies of cells, medium from each well was assayedfor the presence and quantity of secreted antibodies using the ELISA. Ahigh-yielding clone from each transfection was subcloned and expanded toproduce antibody for purification and characterization.Purificaflon of Chimeric and Humanized Antibodies. Chimeric IgGIand IgG3 antibodies were purified from culture medium using protein A-Sepharose and protein G-agarose chromatography, respectively. HumanizedIgGi variants were purified using protein A-Sepharose. The protein concen tration was estimated by measuring the absorbance at 280 ron (assuming1 mg/nil = 1.3 absorbance units). Antibodies were more than 95% pure whenanalyzed Cloning of V Region cDNAs. The murine ABL 364 antibody heavy and light chain V domain cDNAs were cloned using an an chored PCR method (19) . Several independent light chain clones were sequenced and found to be identical; similarly, several heavy chain clones had the same sequence. The nucleotide sequences of the light and heavy chain V regions including the signal peptides and the translated protein sequences are shown in Fig. 1 . The CDRs of each chain are underlined. The VL domain belongs to the mouse K chain group II and uses the jK@segment. The VH domain belongs to the mouse heavy chain subgroup 111(D) and uses the @H3 segment. Construction of Chimeric Antibodies. PCR with appropriate primers was used to copy the VL region, including the signal se quence, from an ABL 364 light chain cDNA clone. The 5' primer was designed to insert a ribosome recognition sequence before the ATG initiation codon, and the 3' primer was designed to insert a splice donor signal after the J segment. The PCR-generated fragment was then cloned into the XbaI site of the pVk expression vector (19) , thus creating a complete chimenc Kchain gene with a mini-intron between the mouse V-J and human C@segments. Similarly, PCR was used to insert the ABL 364 VH region, including a ribosome recognition sequence and J segment splice donor signal, into the XbaI sites of the pVgl and pVg3 vectors (19) . The resulting plasmids contain complete chimeric @â€˜1 and @â€˜3 heavy chain genes, respectively, with a mini intron between the mouse V-D-J segment and the human CH1 exon. The chimeric light chain-containing plasmid was transfected into Sp2/0 mouse myeloma cells along with either the chimeric yl-or chimeric y3-containing plasmid, and cells were selected for expres sion of the gpt gene. Production of antibody by surviving clones of cells was determined using the ELISA. The best producing clones secreted 5 ,i.g/ml chimeric IgGl and 10 @g/ml chimeric IgG3/106 cells/24 h. Chimeric IgGl and IgG3 antibodies secreted into the media were purified using protein A-Sepharose or protein G-agarose, respec tively. The purified IgG1 and IgG3 chimeric antibodies were at least 95% pure when analyzed using SDS-PAGE (data not shown). Effector Functions of Chimeric Antibodies. The activities of the chimeric antibodies against several Lewis Y antigen-positive human tumor cell lines (SKBR5, breast cancer; SW948, colon cancer; and CATO, gastric cancer) were evaluated in the presence of human complement (CDC) or human peripheral mononuclear cells (ADCC). The chimeric IgGl is quite potent against the cells via CDC (IC50 1â€"5 I.Lg/ffil),while the chimeric IgG3 is less potent. Surpris ingly, the murine IgG3 is more potent in CDC than the chimeric IgGl by 2â€"4-fold (Fig. 2) . In contrast, the chimeric IgGl is significantly more potent in ADCC with human PBMCs or monocytes than the murine IgG3 (by 10-fold), whereas the activity of chimeric IgG3 is similar to that of murine IgG3 (Fig. 2) .
Construction of Humanized ABL 364 Antibody. To retain the binding affinity and specificity of the murine antibody in the human ized antibody, the general procedures of Queen et a!. (23) were followed. First, human antibody light and heavy chain V regions with maximum sequence homology to the respective murine ABL 364 V regions were selected to provide the framework sequences for the humanized antibody variable domain to minimize the chance that the CDR conformation would be distorted when grafted onto the human framework. When humanizing previous antibodies, we chose the light chain and heavy chain from the same human antibody to reduce the possibility of incompatibility in the assembly of the two chains. However, based on a sequence homology search against the National Biomedical Foundation Protein Identification Resource, the Tew and Porn antibodies were selected to provide the framework sequences for the humanized ABL 364 light and heavy chain, respectively. Indeed, the ABL 364 light chain variable region shows a significantly higher homology to the Tew framework (77%) than to any other human light chain framework (in the range of 50%). Therefore, Tew was chosen to provide the framework for the humanized light chain variable region, despite the lack of availability of a sequence for the Tew heavy chain. Porn was chosen to provide the framework for the heavy chain because of its high homology to the ABL 364 heavy chain sequence. Next, the computer programs ABMOD and ENCAD (24) were used to construct a molecular model of the ABL 364 variable domain. Inspection of the refined model of murine ABL 364 revealed several amino acid residues in the framework that may have significant contacts with the CDR residues and that differ between the mouse and human sequences. Specifically, residue L54 5cr in the light chain can interact with the CDRs. Residues H73 Asp, H74 Asn, and H109 Tip in the heavy chain also show significant potential interactions with the CDRs. These murine residues were therefore retained in the V region framework of the humanized ABL 364 antibody. Different human light and heavy chain variable regions exhibit substantial amino acid homology within the framework regions (25) . However, a given variable region usually contains amino acids atypical of other human variable regions at several framework positions. The Tew light chain contains such unusual residues at position 108, and the Pom heavy chain at positions 82 and 87. At these positions, we chose to use a consensus human residue rather then the framework residue in the humanized antibody to further minimize potential irnmunogenicity.
As described in â€oeMaterialsand Methods,â€•DNA sequences were synthesized that encoded the desired humanized ABL 364 light and heavy chain V regions along with signal peptides and splice donor sequences. The respective sequences were inserted into the XbaI sites of the pVk and pVgl vectors to generate complete humanized K and â€˜yl genes. The resulting expression plasmids were transiently transfected into S194 cells or stably transfected into Sp2/0 cells as appropriate.
Variants of Humanized ABL 364. As determined with flow cy tometry (â€oeMaterials and Methodsâ€•), the humanized antibody showed a small but measurable 5-fold reduction in affinity compared to the chimeric antibody, and, perhaps more importantly, it was very poorly expressed (Table 1) . Reexamination of the computer model of the variable domain and comparison of the murine and humanized anti body sequences revealed a potential problem at position 95 in the heavy chain. This residue does not contact the CDRs but is important in interfacing with the light chain. A heavy chain mutant was thus constructed to retain the residue 95 from the murine framework (variant D). Several additional variants were constructed by altering amino acids where there is charge change between the murine and humanized framework (variants E-G). Variants D and F improved the binding affinity by a factor of 2.5 and 2, respectively, when analyzed by flow cytometi@y, while the others had no effect (Table 1 ). Two additional variants (H and I) were constructed to combine improve ments in earlier variants. The variant I, which incorporated three additional murine framework residues (residues 42, 44, and 95) from the initial version, showed an affinity within 2-fold of the chimeric IgG1. However, all of the variants remained poorly expressed, when evaluated by transient expression in 5194 cells or by stable expression in Sp2/O cells. The expression levels were 5â€"10-fold lower when compared to the expression of chimeric IgGi . Several variants were constructed by replacing segments of the humanized heavy chain variable region with the analogous murine segments to identify the framework region responsible for the low level of expression. Then additional variants were constructed by substituting each differing residue of the segment with the murine residue and assayed by transient transfections of 5194 cells. A new variant (K) was identified by incorporating the murine framework residue at position 75 into variant I. Variant K improved the expression level by 5-fold, to a level comparable to the chimeric antibody, and also retained binding affin ity within 2-fold of the chimeric antibody (Table 1) . The amino acid sequences of the humanized ABL 364 (variant K) light and heavy chain V regions are shown compared to the murine sequences in Fig.  3 .
Binding Affinities. The binding affinities of the murine IgG3, chimeric IgGi, and humanized IgG1 (variant K) antibodies for the antigen were measured using a competitive binding assay. Serial dilutions of test antibodies were incubated with Lewis Y-positive SKBR5 human breast cancer cells using FITC-labeled ABL 364 as tracer (Fig. 4) . Concentrations of bound and free antibodies were determined in a fluorescence ELISA reader. Affinities calculated according to the method of Berzofsky and Berkower (20) 3.0 X i07, 1.7 X iO@,and 1.2 X iO@M @ for murine, chimeric, and humanized (variant K) ABL 364, respectively. Alternatively, affinities were also measured using iodinated antibodies, and similar results were obtained. In addition, binding to a synthetic Lewis Y covalently bound to BSA also showed comparable specific bindings (data not shown).
CDC. The activities of the humanized variant K against a panel of Lewis Y antigen-positive human tumor cell lines (SKBRS, breast cancer; SW948, colon cancer; SW2, small cell lung cancer; and MCF7, breast cancer) were evaluated in the presence of human complement (CDC). Results similar to those ofchimeric IgGi (Fig. 2) were obtained. The IC50 of the four experiments is shown in Fig. 5 . The humanized antibody showed half-maximal killing at an average of 8 pg/mi versus 4.5 p.g/ml for chimeric antibody. The slight loss of activity may reflect the slightly reduced affinity of the humanized antibody compared to the chimeric antibody. The murine antibody is slightly more potent (average IC50 at 2 @g/ml)than the chimeric antibody in CDC, probably a result of the cooperativity effects of the murine y3 constant region (discussed below).
ADCC. The antibody-dependent cytotoxicity of the humanized ABL 364 (variant K) was also evaluated against the panel of four tumor cell lines. The IC50 of the four experiments is shown in Fig. 6 and remained consistent with the results for the chimeric IgGi deter mined earlier (Fig. 2) . Both humanized and chimeric antibodies (av erage IC50 at 1 and 0.5 @g/m1, respectively) were significantly better than the murine antibody (average IC50 at 8 @g/ml),presumably (29) that the chimeric IgGl of another Lewis Y antibody, BR96, showed stronger antitumor effects than the murine IgG3 in a nude mice model. Surprisingly, the murine antibody was more effective in mediating CDC than chimeric IgGl (2â€"3-fold),which was in turn more effective than the chimeric IgG3. The mechanism of enhanced CDC by the murine IgG3 is not fully understood, although it has been speculated that intermolecular interactions between Fc regions of IgG3 molecules may lead to enhanced binding to multivalent antigens or multivalent interaction with Clq molecules (30) . The difference in effectiveness of the antibodies on the various cell lines is probably due to differences in the expression of Lewis Y on the cell surface. Indeed, this observation has been reported by another murmneIgG3 against the disialoganglioside GD3, which showed that the level of cell lysis mediated by this antibody is correlated with GD3 antigen density on the cell surface (3 1). Despite the significant toxicity of murine IgG3 toward many tumor cell lines, the chimeric IgG1 has proven to be more desirable, particularly with its more potent ADCC activities and the potential reduction of irnmunogenicity in humans.
To reduce further the potential immunogenicity of chimeric anti bodies, humanized antibodies were constructed. Antibodies of IgGi isotype were chosen to take advantage of its more potent effector functions. The humanization of antibodies is still not routine, with many investigators reporting significant loss of binding affinity to ward the antigen when CDRs from a murine antibody are grafted into a human framework (32, 33) . Our method of choosing a highly homologous human framework and then using computer modeling has often allowed us to humanize a murine antibody without signif icant loss of affinity in a single try (19, 23, 34, 35) . However, in the case of ABL 364, the first humanized version generated has a small equally well to the CDRs of both the murine and the humanized antibody (22) . Groups of three monkeys received a single i.v. bolus injection of 0.8 mg/kg body weight of either the murine or humanized ABL 364. As shown in Fig. 7 , the @3 half-life of the murine antibody is 1.9 days. In contrast, the j3 half-life of humanized antibody ranged from 14 to 20 days, with a mean of 16.3 days.
DISCUSSION
The potential of an antibody to lyse tumor cells is determined in the major part by the class of the constant regions. Human IgGl and IgG3 have been shown to be the most effective isotypes in mediating CDC and ADCC toward tumor cells (26â€"28).We therefore initially con structed chimeric antibodies of both isotypes to evaluate their in vitro 
but measurable loss of affinity of about 5-fold. Using PCR to quickly create variants and a fast relative affinity measurement based on flow cytometiy, we were able to rapidly generate and evaluate a series of antibody variants and obtain a humanized antibody which retained affin ity to within 2-fold of the chimeric antibody. The observation that the murine antibody has a slightly higher apparent affinity than the chimeric antibody, despite having an identical variable domain, was intriguing. This can be due to a unique property ofthe murine IgG3 isotype, in which a noncovalent intermolecular interaction of Fc domains may lead to a higher binding avidity (30) . The binding affinity ofABL 364 to the Lewis Y antigen, on the order of l0@ M @ , is common among antibodies generated against carbohydrate antigens (36, 37) .
In the course of constructing the humanized ABL 364 antibody, we also observed that substitution of a single amino acid in the heavy chain framework can significantly affect the ability of the antibody to be expressed. We demonstrated that changing residue 75 in the humanized heavy chain framework from Ser to Ala caused the anti body to be secreted at a 5â€"10-fold higher level when transiently expressed in 5194 cells. Similar results were observed when a popu lation of clones generated by stable Sp2/0 transfections were corn pared. The effect of this substitution was confirmed by the reverse experiment of mutating the murine framework residue 75 in the chimeric antibody from Ala to Ser and observing a corresponding decrease in expression of the antibody by transfected 5194 cells (data not shown). It is unclear how residue 75 affects the ability of the antibody to be expressed, although previous publications have re ported that a single amino acid substitution in the A or K light chain variable region can prevent secretion of an antibody (38â€"40).In one case, it was shown that the immunoglobulin chain was arrested in the endoplasmic reticulum (40) .
Since Lewis Y antigen is expressed in a significant percentage of human carcinomas of epithelial cell origin including breast, colon, gastric, and lung cancers, there is considerable interest in its use as a target for antibody therapy or diagnosis. Several murine monoclonal antibodies have been reported reactive with this antigen (4, 5) . (2) . In vitro, the antibody exhibits potent ADCC and CDC activities against many tumor cell lines (6, 7) . More sigmfi candy, this antibody has been tested in five human clinical trials including two Phase I/il trials in relapsed small cell lung cancer and metastatic breast cancer (8, 9) . However, the clinical utility of ABL 364, like that of other murine antibodies, was limited by the HAMA response and its short half-life. We have therefore constructed a humanized ABL 364 to fully utilize the potential of this antibody in human therapy. Indeed, recent clinical trials of two humanized anti bodies against interleukin 2 receptor (43) and CD33 (44) for treatment of acute graft-versus-host disease and myeloid leukemia, respectively, have shown that these humanized antibodies did not develop any HAMA response in human patients. The humanized ABL 364 (variant K) retains the binding affinity of the murine antibody and is more effective in activation of human effector cells for tumor cell destruction. The pharmacokinetics of the humanized ABL 364 (variant K) in rhesus monkeys has also been studied and compared with that of the parent murine antibody. The (3 half-life of the murine antibody is 1.9 days, similar to that observed in cancer patients (11, 12) . In contrast, the (3half-life of humanized ABL 364 is 14â€"20days, similar to that of human IgGi in humans (13, 45, 46) . Moreover, the fact that a circulating level of humanized ABL 364
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on May 1, 2017. © 1996 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from was maintained in the monkeys for 90 days and accelerated clearance was not observed (Fig. 7) suggests that there was little or no monkey antibody response against humanized ABL 364. Based on these prop erties, the humanized ABL 364 may be a promising candidate for immunotherapy of certain tumors. The ability of the murmne antibody to reduce micrometastatic cells disseminated to the bone marrow suggests that humanized ABL 364 may be most effective in a minimal residual disease setting to increase disease-free survival time or over all survival. The actual efficacy of the antibody will need to be evaluated in clinical trials.
